Background and Purpose
======================

Carotid ultrasound is used to measure intima-media complex thickness (IMT) as a marker of atherosclerosis, as well as a risk factor for cardiovascular events^[@bib1]--[@bib4])^. In Western countries, IMT has been reported to be attenuated by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) that can decrease cholesterol biosynthesis in the liver^[@bib5]--[@bib9])^. However, the effect of HMG-CoA reductase inhibitors on IMT has not been well established in Japan. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) trial is a multicenter, prospective, randomized, open-label, parallel group trial of secondary stroke prevention using pravastatin 10 mg/day (usual dose in Japan) in the stroke patients with hyperlipidemia. The aim of this trial is to examine whether pravastatin prevents stroke recurrence in Japanese patients with noncardioembolic ischemic stroke. The J-STARS Echo Study is a substudy of the J-STARS study that aims to explore the pleiotropic effects of regular statin therapy on the changes of carotid atherosclerosis assessed by ultrasonography. Baseline characteristics, baseline mean and maximum IMTs, and the atherosclerosis factors correlated with the baseline mean and maximum IMTs were examined.

Patients and Methods
====================

Study Design
------------

The study design methods of the J-STARS Echo Study were described elsewhere^[@bib10],\ [@bib11])^; thus, the methods are stated briefly here. The protocol and informed consent form of the present substudy were approved by the institutional review board of each center, and written informed consent was obtained from each patient together with the main trial. The J-STARS Echo Study is registered with ClinicalTrials.gov (NCT00361530) and the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (C000000212) separately from J-STARS (NCT00221104, UMIN C000000207).

Patient Population
------------------

Patients from 61 hospitals with certified sonographers in the J-STARS Echo Study were enrolled in this substudy. The inclusion criteria for the main trial were as follows: (1) age between 45 and 80 years; (2) clinical diagnosis of noncardioembolic ischemic stroke developing within the preceding month to 3 years; and (3) history of hyperlipidemia with serum total cholesterol levels maintained between 4.65 and 6.21 mmol/L (180 and 240 mg/dL), without the use of statins. Additional exclusion criteria for the main trial have been described in elsewhere^[@bib10],\ [@bib11])^.

Randomization and Treatment
---------------------------

The patients were enrolled through a web-based registration and follow-up system for the main trial. Patients assigned to the pravastatin group received pravastatin 10 mg/day, and those in the control group received no statin treatment, although other drugs were administered when necessary.

Carotid Ultrasonography
-----------------------

Carotid ultrasonography was performed in each participating institute by well-trained physicians or laboratory technicians who were certified as expert examiners for this study. Baseline examinations were performed at the time of enrollment in the study. The examination methods have been described in elsewhere^[@bib11])^.

Carotid IMT Measurements
------------------------

Videotapes or CD-Rs of the ultrasonography were sent to the J-STARS ECHO office for assessment, including kinetic measurements. All measurements were performed by a well-trained technician who was blinded to all clinical information.

Carotid IMT measurement methods have been described in elsewhere^[@bib11])^. Still images (640 × 480 pixels) were imported from the videotapes or CD-Rs via a video port with a resolution of 1 pixel corresponding to 0.1 mm (**[Fig. 1](#F1){ref-type="fig"}**). All still images were then imported into an IMT measurement software (IntimaScope; Mediacross, Tokyo, Japan), and IMT was measured on the distal wall in a continuous 2-cm section on the central side of the common carotid artery (CCA) bifurcation^[@bib12])^. This software was programmed to automatically draw 2 lines at the junctions of the intimamedia complex with the blood and the adventitia, and it was capable of measuring distances down to 0.01 mm^[@bib13])^. Mean and maximum values of IMT in a 2-cm continuous section of the distal CCA were calculated automatically, and plaque thickness was similarly measured at the site of each plaque. Pivotal parameters for analysis were mean IMT (right, left, and mean of right and left) and maximum IMT (right, left, and thicker value of right and left) of the distal wall of the CCA in the above-mentioned 2-cm section.

![B-mode ultrasound image sample of the CCA showing the measurement of IMT by Intima-Scope\
A. Still images (640 × 480 pixels) were imported from the videotapes or CD-Rs via a video port with a resolution of 1 pixel corresponding to 0.1 mm.\
B. Measurement of a CCA section.\
IMT measured using the long-axis view of each CCA. An image is obtained in the region including the far wall of the CCA between the tip of the bifurcation site and a point 2-cm proximal.\
C. Standardized longitudinal B-mode of CCA.\
D. Automated measurement of IMT from the far wall.\
IMT is automatically calculated using a computer-assisted measurement system (IntimaScope; Mediacross, Tokyo, Japan).](jat-25-359-g001){#F1}

Statistical Analysis
--------------------

Baseline characteristics between the pravastatin and control groups and between the patients included in the J-STARS Echo Study and those not included in the J-STARS Echo Study were compared using the chi-square test, *t*-test, and Wilcoxon rank-sum test, as appropriate. The mean and maximum IMTs stratified by baseline characteristics were compared using nonpaired *t*-test. Multivariable analyses to assess factors associated with mean and maximum IMTs were performed using stepwise multiple linear regression analysis with age, sex, weight, body mass index, diabetes mellitus (DM), smoking habit, total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, categories of blood pressure, glomerular filtration, creatinine clearance, urinary protein, chronic kidney disease, subtype of stroke, size of responsible infarction, location of infarction vessel, carotid bruit, and atrial flutter/fibrillation as independent variables. In the stepwise multiple linear regression analysis, independent variables were selected by the method of predicted residual error sum of squares statistic. The factors used as variables for the stepwise multiple linear regression analysis are described in **[Table 1](#T1){ref-type="table"}**.

###### Baseline characteristics

                                                                                                                  Pravastatin group   Control group   *P* value
  --------------------------------------------------------------- ----------------------------------------------- ------------------- --------------- -----------
  Age, y                                                                                                          66.4 ± 8.2          66.4 ± 8.4      0.96
  Male                                                                                                            255 (65.7)          275 (67.9)      0.51
  Height, cm                                                                                                      159.6 ± 8.8         159.7 ± 8.3     0.79
  Weight, kg                                                                                                      60.8 ± 9.8          60.5 ± 10.0     0.64
  Body mass index, kg/m^2^                                                                                        23.8 ± 2.9          23.7 ± 3.0      0.49
  Blood pressure, mmHg[\*](#tf1){ref-type="table-fn"}             SBP                                             136.5 ± 17.6        135.8 ± 16.9    0.56
                                                                  DBP                                             79.1 ± 11.7         78.5 ± 10.5     0.47
  Risk factor                                                     Hypertension                                    294 (75.8)          321 (79.3)      0.24
                                                                  Diabetes mellitus                               89 (22.9)           107 (26.4)      0.26
                                                                  Coronary artery disease                         15 (3.9)            20 (4.9)        0.46
                                                                  Smoking habit^[†](#tf2){ref-type="table-fn"}^   201 (51.8)          218 (53.8)      0.52
  Medication                                                      Lipid-lowering agents                           28 (7.2)            40 (9.9)        0.18
                                                                  Antihypertensive                                233 (60.1)          253 (62.5)      0.48
                                                                  Glucose-lowering agents                         70 (18.0)           80 (19.8)       0.54
                                                                  Anti-thrombotics                                356 (91.8)          369 (91.1)      0.75
  Laboratory data, mg/dL^[‡](#tf3){ref-type="table-fn"}^          T-chol                                          211.8 ± 25.8        209.3 ± 25.4    0.18
                                                                  HDL-chol                                        53.8 ± 16.3         52.2 ± 14.8     0.17
                                                                  LDL-chol                                        130.9 ± 25.4        130.3 ± 24.5    0.74
                                                                  TG                                              139.7 ± 71.1        142.8 ± 70.7    0.54
                                                                  FBS                                             116.3 ± 39.0        115.8 ± 36.2    0.85
  Subtype of stroke                                               Atherothrombotic infarction                     93 (24.0)           102 (25.2)      0.99
                                                                  Lacunar infarction                              251 (64.7)          275 (67.9)      
                                                                  Undetermined                                    44 (11.3)           28 (6.9)        
  Size of infarction^[§](#tf4){ref-type="table-fn"}^              Small                                           302 (77.8)          297 (73.3)      0.22
                                                                  Medium                                          72 (18.6)           81 (20.0)       
                                                                  Large                                           2 (0.5)             8 (2.0)         
  Location of infarction                                          Cortical artery                                 61 (15.7)           73 (18.0)       0.61
                                                                  Perforating artery                              298 (76.8)          295 (72.8)      
                                                                  Both                                            17 (4.4)            18 (4.4)        
  Responsible vessel^[‖](#tf5){ref-type="table-fn"}^              ACA                                             5 (1.3)             7 (1.7)         0.46
                                                                  MCA                                             241 (62.1)          267 (65.9)      
                                                                  PCA                                             30 (7.7)            24 (5.9)        
                                                                  VB                                              94 (24.2)           80 (19.8)       
                                                                  BZ                                              6 (1.5)             8 (2.0)         
  Baseline NIHSS score, median[\*\*](#tf6){ref-type="table-fn"}   0 (IQR 0--2)                                    1 (IQR 0--2)        0.02            
  Baseline mRS score^[††](#tf7){ref-type="table-fn"}^             0                                               123 (31.7)          130 (32.1)      0.58
                                                                  1                                               185 (47.7)          176 (43.5)      
                                                                  2                                               61 (15.7)           74 (18.3)       
                                                                  3                                               8 (2.1)             11 (2.7)        
                                                                  4                                               11 (2.8)            13 (3.2)        

*n* (%) or mean ± SD

SBP: systolic blood pressure; DBP: diastolic blood pressure

Smoking habit including current smoker and past smoker

T-chol: total cholesterol; HDL-chol: high density lipoprotein cholesterol; LDL-chol: low density lipoprotein cholesterol; TG: triglyceride; FBS: fasting blood sugar

Size of infarction: small was defined as lesion within a diameter of 1.5 cm, large was defined as a lesion more than half of the cerebral lobe. Medium was defined as between small and large.

ACA: anterior cerebral artery; MCA: middle cerebral artery; PCA: posterior cerebral artery; VB: vertebrobasilar artery; BZ: border zone

NIHSS, National Institutes of Health Stroke Scale

mRS, modified Rankin Scale

All analyses were performed using SAS software (Cary, NC, USA), and the level of significance was set at *p* \< 0.05 (two-tailed).

Results
=======

Among the 123 participating sites in the main J-STARS study, 61 centers had certified sonographers available. From these 61 centers, 941 patients were enrolled in the main J-STARS study, and 864 patients agreed to participate in the J-STARS Echo Study between March 2004 and February 2009 (**[Fig. 2](#F2){ref-type="fig"}**). Among the 864 patients, 71 patients did not undergo ultrasound evaluation. Thus, 793 patients were included in this study \[530 men (66.8%), 66.4 ± 8.3 years old\]. Of these 793 patients, 388 patients (49%) were assigned to receive pravastatin (pravastatin group), and 405 (51%) did not receive any statins (control group).

![Patient selection flow chart](jat-25-359-g002){#F2}

The baseline characteristics of the patients in this substudy and the remaining 796 patients in the J-STARS study were generally similar (**[Supplementary Table 1](#T6){ref-type="table"}**). **[Table 1](#T1){ref-type="table"}** shows the baseline characteristics of the patients in the pravastatin and control groups enrolled in the J-STARS Echo Study. There were no significant differences between the two groups, except for the baseline National Institutes of Health Stroke Scale (NIHSS) scores: median, 0 (IQR 0--2) vs. 1 (IQR 0--2), respectively (*p* = 0.02).

###### Baseline characteristics of patients who were and were not included in the J-STARS Echo Study

                                                                                             Included in J-STARS Echo Study   Not included in J-STARS Echo Study   *P*-Value
  ---------------------------------------------------------------- ------------------------- -------------------------------- ------------------------------------ -----------
  Age, years                                                                                 66.4 ± 8.3                       66.0 ± 8.6                           0.32
  Male                                                                                       530 (66.8)                       557 (71.0)                           0.08
  Height, cm                                                                                 159.7 ± 8.5                      160.9 ± 8.8                          \< 0.01
  Weight, kg                                                                                 60.6 ± 9.9                       61.6 ± 10.3                          0.07
  Body mass index, kg/m^2^                                                                   23.7 ± 3.0                       23.7 ± 3.2                           0.95
  Blood pressure, mmHg[\*](#tf19){ref-type="table-fn"}             SBP                       136.2 ± 17.3                     138.1 ± 18.3                         0.03
                                                                   DBP                       78.8 ± 11.1                      79.9 ± 11.5                          0.06
  Risk factor                                                      Hypertension              615 (77.6)                       585 (74.5)                           0.16
                                                                   Diabetes mellitus         196 (24.7)                       173 (22.0)                           0.21
                                                                   Coronary artery disease   35 (4.4)                         46 (5.9)                             0.17
                                                                   Smoking habit             419 (52.8)                       427 (54.4)                           0.31
  Medication                                                       Lipid-lowering agents     68 (8.6)                         50 (6.4)                             0.10
                                                                   Antihypertensive          486 (61.3)                       467 (59.5)                           0.55
                                                                   Glucose-lowering agents   150 (18.9)                       142 (18.1)                           0.70
                                                                   Anti-thrombotics          725 (91.4)                       713 (90.8)                           0.86
  Laboratory data, mg/dL^[†](#tf20){ref-type="table-fn"}^          T-chol,                   210.5 ± 25.5                     209.6 ± 23.2                         0.47
                                                                   HDL-chol,                 53.0 ± 15.5                      53.9 ± 16.0                          0.23
                                                                   LDL-chol,                 130.6 ± 24.9                     128.2 ± 23.9                         0.05
                                                                   TG,                       141.3 ± 70.9                     143.3 ± 77.5                         0.63
                                                                   FBS,                      116.0 ± 37.6                     119.2 ± 44.1                         0.12
  Subtype of stroke                                                Atherothrombotic          195 (24.6)                       206 (26.2)                           0.22
                                                                   Lacunar                   526 (66.3)                       480 (61.1)                           
                                                                   Undetermined              72 (9.1)                         99 (12.6)                            
  Size of infarction^[‡](#tf21){ref-type="table-fn"}^              Small                     599 (75.5)                       573 (73.0)                           0.16
                                                                   Medium                    153 (19.3)                       177 (22.5)                           
                                                                   Large                     10 (1.3)                         9 (1.1)                              
  Location of infarction                                           Cortical                  134(16.9)                        158 (20.1)                           0.27
                                                                   Perforating               593 (74.8)                       566 (72.1)                           
                                                                   Both                      35 (4.4)                         35 (4.4)                             
  Responsible vessel^[§](#tf22){ref-type="table-fn"}^              ACA                       12 (1.5)                         20 (2.5)                             \< 0.01
                                                                   MCA                       508 (64.1)                       439 (55.9)                           
                                                                   PCA                       54 (6.8)                         66 (8.4)                             
                                                                   VB                        174 (21.9)                       205 (26.1)                           
                                                                   BZ                        14 (1.8)                         29 (3.7)                             
  Baseline NIHSS score ^[‖](#tf23){ref-type="table-fn"}^, median                             1.0 (IQR0--2)                    1.0 (IQR0--2)                        0.05
  Baseline mRS score[\*\*](#tf24){ref-type="table-fn"}             0                         253 (31.9)                       294 (37.5)                           0.02
                                                                   1                         361 (45.5)                       321 (40.9)                           
                                                                   2                         135 (17.0)                       120 (15.3)                           
                                                                   3                         19 (2.4)                         22 (2.9)                             
                                                                   4                         24 (3.0)                         13 (1.7)                             

*n* (%) or Mean ± SD

SBP: systolic blood pressure, DBP: diastolic blood pressure

T-chol: total cholesterol, HDL-chol: high density lipoprotein cholesterol, LDL-chol: low density lipoprotein cholesterol, TG: triglyceride, FBS: fasting blood sugar

Size of infarction: small was defined as lesion within diameter 1.5 cm, large was defined as lesion more than half of cerebral lobe. Medium was defined as between small and large.

ACA: anterior cerebral artery, MCA: middle cerebral artery, PCA: posterior cerebral artery, VB: vertebrobasilar artery, BZ: border zone

National Institutes of Health Stroke Scale

modified Rankin Scale

Overall mean IMT was 0.89 ± 0.15 mm: 0.89 ± 0.15 mm in the pravastatin group and 0.89 ± 0.15 mm in the control group (*p* = 0.99). Overall maximum IMT was 1.19 ± 0.32 mm: 1.20 ± 0.33 mm in the pravastatin group and 1.18 ± 0.31 mm in the control group (*p* = 0.56) (**[Table 2](#T2){ref-type="table"}**).

###### Baseline mean and maximum intima-media complex thickness

                                               Total              Pravastatin Group   Control Group      *P* value
  -------------------------------------------- ------------------ ------------------- ------------------ -----------
  Mean intima-media complex thickness, mm                                                                
  Left (mm)                                                                                              
      Mean ± SD                                0.89 ± 0.18        0.89 ± 0.17         0.89 ± 0.18        0.98
      Median, IQR                              0.86, 0.77--0.98   0.87, 0.77--0.99    0.86, 0.78--0.98   
  Right (mm)                                                                                             
      Mean ± SD                                0.89 ± 0.16        0.89 ± 0.16         0.88 ± 0.15        0.91
      Median, IQR                              0.87, 0.78--0.97   0.87, 0.78--0.97    0.87, 0.78--0.96   
  Average of both sides (mm)                                                                             
      Mean ± SD                                0.89 ± 0.15        0.89 ± 0.15         0.89 ± 0.15        0.99
      Median, IQR                              0.87, 0.78--0.97   0.87, 0.78--0.97    0.87, 0.78--0.96   
                                                                                                         
  Maximum intima-media complex thickness, mm                                                             
  Left (mm)                                                                                              
      Mean ± SD                                1.11 ± 0.29        1.11 ± 0.29         1.10 ± 0.29        0.59
      Median, IQR                              1.05, 0.92--1.22   1.06, 0.92--1.24    1.04, 0.93--1.19   
  Right (mm)                                                                                             
      Mean ± SD                                1.10 ± 0.29        1.10 ± 0.30         1.10 ± 0.27        0.74
      Median, IQR                              1.05, 0.93--1.19   1.05, 0.92--1.20    1.05, 0.93--1.18   
  Thicker value of the two sides (mm)                                                                    
      Mean ± SD                                1.19 ± 0.32        1.20 ± 0.33         1.18 ± 0.31        0.56
      Median, IQR                              1.12, 0.98--1.29   1.13, 0.98--1.32    1.12, 0.98--1.27   

SD, standard deviation; IQR, interquartile range

**[Table 3](#T3){ref-type="table"}** shows relationships between baseline IMT and potentially associated factors in univariate analysis. Women, patients aged 65 years or older, category of blood pressure, hypertension, DM, smoking habit, HDL cholesterol less than 50 mg/ml, chronic kidney disease, and carotid bruit were positively associated with mean IMT. Stepwise multiple linear regression analysis included those factors that had differences in the univariate analysis. Age (per 10 years) (*p* \< 0.001), smoking habit (*p* = 0.004), category of blood pressure (*p* = 0.006), HDL cholesterol (per 10 mg/dl) (*p* = 0.008), and DM (*p* = 0.010) were selected and significantly associated with mean IMT (**[Table 4](#T4){ref-type="table"}**).

###### Baseline intima-media complex thickness by potentially associated factors

                                                                                              *N*   Mean IMT (mm), mean ± SD   *P*-Value   Maximum IMT (mm), mean ± SD   *P* value
  ------------------------------------------------------------- ----------------------------- ----- -------------------------- ----------- ----------------------------- -----------
  Age, years                                                    \< 65                         326   0.86 ± 0.15                \< 0.01     1.14 ± 0.29                   \< 0.01
                                                                ≥ 65                          467   0.91 ± 0.15                            1.22 ± 0.34                   
  Sex                                                           Male                          530   0.90 ± 0.15                0.01        1.21 ± 0.33                   0.01
                                                                Female                        263   0.87 ± 0.16                            1.15 ± 0.31                   
  Weight, kg                                                    \< 60                         361   0.88 ± 0.16                0.11        1.18 ± 0.35                   0.48
                                                                ≥ 60                          430   0.90 ± 0.15                            1.20 ± 0.30                   
  Body mass index, kg/m^2^                                      \< 24                         421   0.88 ± 0.16                0.13        1.18 ± 0.35                   0.2
                                                                ≥ 24                          368   0.90 ± 0.15                            1.21 ± 0.29                   
  Hypertension                                                  Absent                        178   0.84 ± 0.14                \< 0.01     1.13 ± 0.31                   0.01
                                                                Present                       615   0.90 ± 0.15                            1.21 ± 0.32                   
  Diabetes mellitus                                             Absent                        597   0.88 ± 0.15                0.01        1.17 ± 0.31                   \< 0.01
                                                                Present                       196   0.91 ± 0.16                            1.25 ± 0.35                   
  Smoking habit                                                 None                          370   0.87 ± 0.15                0.02        1.16 ± 0.31                   0.03
                                                                Past                          280   0.91 ± 0.15                            1.22 ± 0.32                   
                                                                Current                       139   0.89 ± 0.16                            1.22 ± 0.36                   
  Total cholesterol, mg/dL                                      \< 210                        395   0.89 ± 0.15                0.62        1.20 ± 0.34                   0.43
                                                                ≥ 210                         395   0.89 ± 0.15                            1.18 ± 0.31                   
  HDL cholesterol, mg/dL                                        \< 50                         384   0.91 ± 0.15                \< 0.01     1.22 ± 0.30                   \< 0.01
                                                                ≥ 50                          404   0.87 ± 0.16                            1.16 ± 0.34                   
  LDL cholesterol, mg/dL                                        \< 130                        385   0.89 ± 0.15                0.77        1.19 ± 0.34                   0.89
                                                                ≥ 130                         397   0.89 ± 0.16                            1.16 ± 0.31                   
  Triglyceride, mg/dL                                           \< 130                        414   0.88 ± 0.15                0.35        1.18 ± 0.33                   0.65
                                                                ≥ 130                         376   0.89 ± 0.15                            1.20 ± 0.31                   
  Categories of blood pressure[\*](#tf8){ref-type="table-fn"}   Category 1                    83    0.91 ± 0.15                \< 0.01     1.21 ± 0.30                   0.18
                                                                Category 2                    274   0.91 ± 0.15                            1.21 ± 0.31                   
                                                                Category 3                    435   0.87 ± 0.15                            1.17 ± 0.34                   
  eGFR, ml/min/1.73m^2[†](#tf9){ref-type="table-fn"}^           \< 30                         4     0.85 ± 0.16                0.09        1.21 ± 0.33                   0.57
                                                                30--59                        187   0.90 ± 0.17                            1.21 ± 0.33                   
                                                                ≥ 60                          60    0.88 ± 0.15                            1.18 ± 0.32                   
  Creatinine clearance, ml/min                                  \< 30                         4     0.82 ± 0.16                0.25        1.17 ± 0.35                   0.52
                                                                30--59                        183   0.90 ± 0.17                            1.21 ± 0.39                   
                                                                ≥ 60                          604   0.88 ± 0.15                            1.18 ± 0.30                   
  Urinary protein                                               Absent                        689   0.89 ± 0.15                0.27        1.19 ± 0.33                   0.63
                                                                Present                       83    0.91 ± 0.15                            1.21 ± 0.31                   
  Chronic kidney disease                                        Absent                        602   0.88 ± 0.15                0.04        1.18 ± 0.32                   0.29
                                                                Present                       191   0.91 ± 0.16                            1.21 ± 0.33                   
  Subtype of stroke                                             Atherothrombotic infarction   195   0.90 ± 0.16                0.51        1.21 ± 0.34                   0.49
                                                                Lacunar infarction            526   0.88 ± 0.15                            1.18 ± 0.31                   
                                                                Other                         72    0.89 ± 0.18                            1.19 ± 0.35                   
  Size of infarction^[‡](#tf10){ref-type="table-fn"}^           None                          27    0.86 ± 0.14                0.34        1.11 ± 0.26                   0.56
                                                                Small                         599   0.88 ± 0.15                            1.19 ± 0.32                   
                                                                Medium                        153   0.90 ± 0.17                            1.21 ± 0.36                   
                                                                Large                         10    0.94 ± 0.14                            1.20 ± 0.25                   
  Location of infarction                                        None                          27    0.86 ± 0.14                0.49        1.11 ± 0.26                   0.59
                                                                Cortical artery               134   0.90 ± 0.16                            1.20 ± 0.34                   
                                                                Perforating artery            593   0.89 ± 0.15                            1.19 ± 0.33                   
                                                                Both                          10    0.91 ± 0.13                            1.20 ± 0.24                   
  Responsible vessel ^[§](#tf11){ref-type="table-fn"}^          None                          2     0.86 ± 0.14                0.71        1.11 ± 0.26                   0.46
                                                                ACA                           12    0.89 ± 0.11                            1.15 ± 0.17                   
                                                                MCA                           508   0.89 ± 0.15                            1.19 ± 0.30                   
                                                                PCA                           54    0.86 ± 0,15                            1.14 ± 0.36                   
                                                                VB-territory                  174   0.90 ± 0.16                            1.22 ± 0.39                   
                                                                Border Zone                   14    0.89 ± 0.11                            1.18 ± 0.19                   
  Carotid bruit                                                 Absent                        767   0.89 ± 0.15                0.04        1.19 ± 0.32                   0.43
                                                                Present                       18    0.96 ± 0.20                            1.25 ± 0.34                   
  Atrial flutter/fibrillation                                   Absent                        775   0.88 ± 0.15                0.51        1.19 ± 0.32                   0.16
                                                                Present                       10    0.92 ± 0.15                            1.33 ± 0.34                   

IMT, intima media complex thickness; SD, standard deviation;

Category 1: SBP ≥ 160 mmHg or DBP ≥ 100 mmHg; Category 2: SBP 140--159 mmHg or DBP 90--99 mmHg; Category 3: SBP \< 140 mmHg and DBP \< 90 mmHg.

eGFR, estimated glomerular filtration rate

Size of infarction: Small was defined as a lesion within a diameter of 1.5 cm, large was defined as a lesion more than half of a cerebral lobe. Medium was defined between small and large.

ACA, anterior cerebral artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; VB, vertebrobasilar artery

###### Multiple regression analysis for mean intima-media complex thickness

  Variable                                                       Parameter Estimate   Standard Error   Pr \> \|t\|
  -------------------------------------------------------------- -------------------- ---------------- -------------
  Age (/10 years)                                                0.044                0.007            \< 0.001
  Smoking habit [\*](#tf12){ref-type="table-fn"}                 0.022                0.007            0.004
  Category of blood pressure^[†](#tf13){ref-type="table-fn"}^    0.022                0.008            0.006
  HDL cholesterol^[‡](#tf14){ref-type="table-fn"}^ (/10 mg/dL)   −0.009               0.003            0.008
  Diabetes mellitus                                              0.033                0.013            0.010
  Size of responsible lesion^[§](#tf15){ref-type="table-fn"}^    0.017                0.011            0.125

Smoking habit including current smoker and past smoker

Category of blood pressure: Category 1, SBP ≥ 160 mmHg or DBP ≥ 100 mmHg; Category 2, SBP 140--159 mmHg or DBP 90--99 mmHg; Category 3, SBP \< 140 mmHg and DBP \< 90 mmHg

HDL-cholesterol: High density lipoprotein cholesterol

Size of responsible lesion: small, medium, or large

Similarly, women, patients aged 65 years or older, hypertension, DM, smoking habit, and HDL cholesterol less than 50 mg/ml were positively associated with maximum IMT in the univariate analysis. Age (per 10 years) (*p* \< 0.001), smoking habit (*p* = 0.001), DM (*p* = 0.002), and HDL cholesterol (*p* = 0.036) were selected and significantly associated with maximum IMT in the stepwise multiple linear regression analysis (**[Table 5](#T5){ref-type="table"}**).

###### Multiple regression analysis for maximum intima-media complex thickness

  Variable                                                       Parameter Estimate   Standard Error   Pr \> \|t\|
  -------------------------------------------------------------- -------------------- ---------------- -------------
  Age (/10 years)                                                0.076                0.014            \< 0.001
  Smoking habit[\*](#tf16){ref-type="table-fn"}                  0.053                0.016            0.001
  Diabetes mellitus                                              0.084                0.027            0.002
  HDL cholesterol (/10 mg/dL)^[†](#tf17){ref-type="table-fn"}^   −0.016               0.007            0.036
  Category of blood pressure^[‡](#tf18){ref-type="table-fn"}^    0.025                0.017            0.146

Smoking habit including current smoker and past smoker

HDL-cholesterol, High density lipoprotein cholesterol

Category 1: SBP ≥ 160 mmHg or DBP ≥ 100 mmHg; Category 2: SBP 140--159 mmHg or DBP 90--99 mmHg; Category 3: SBP \< 140 mmHg and DBP \< 90 mmHg

Discussion
==========

The J-STARS Echo Study enrolled the largest sample size in Asia to assess the relationship between IMT progression and statin use, comparable to previous trials from Western countries. Baseline characteristics and contributing factors to the baseline mean and maximum IMTs were assessed in Japanese noncardioembolic stroke patients. Age, smoking habit, category of blood pressure, DM, and HDL cholesterol were independently related to the baseline mean IMT, and they were also related to the baseline maximum IMT, except for category of blood pressure.

Carotid IMT has been used to define atherosclerosis in a number of recent clinical trials for cardiovascular diseases and stroke. The relationship between IMT and statin use has been assessed in many studies and trials from Western countries, but there are few trials, with a small number of patients, from Asian countries. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial is the largest study, including 4731 patients who had a stroke or transient ischemic attack, which showed the effect of statin use on reduction in the risk of stroke. However, the SPARCL trial did not include carotid IMT as a clinical outcome^[@bib14])^. The present study included the largest sample size of noncardioembolic stroke patients, examining the effect of statin on the progression of carotid IMT.

The Japanese population has been reported to have thinner carotid IMTs than Western populations, probably due to the differences in the lifetime period levels of obesity through adipocytokines or certain levels of inflammation through lipoprotein distribution, rather than differences in genetic factors^[@bib15]--[@bib19])^. Koreans and Japanese Americans have been found to have thicker IMTs than native Japanese, and this might explain such risk factors, rather than genetic factors, contributing to carotid IMT^[@bib15],\ [@bib20])^. **[Supplementary Tables 2](#T7){ref-type="table"}** and **[3](#T8){ref-type="table"}** show previous trials that reported the association between IM and statin use^[@bib6],\ [@bib7],\ [@bib21]--[@bib26])^. Interestingly, the baseline mean and maximum IMTs in the present study were similar to those from previous trials that examined the effects of statin therapy in Western and Asian countries (**[Supplementary Table 2](#T7){ref-type="table"}**). Because this study focused on patients with a history of ischemic stroke and they had a high prevalence of atherosclerotic risk factors, such as aging, high blood pressure, and DM (**[Supplementary Table 3](#T8){ref-type="table"}**), carotid IMT assessed in the present study may be higher than that in other non-stroke-related Japanese populations^[@bib20]^, ^[@bib27])^.

###### Carotid intima-media complex thickness in the present and previous studies

  Study                       Year   Mean IMT, mm                                                 Maximum IMT, mm
  --------------------------- ------ ------------------------------------------------------------ ------------------------------------------------------------
  ACAPS^[@bib12]^             1994   1.14 ± 0.19                                                  NA
  CAIUS^[@bib5]^              1996   0.88 ± 0.18                                                  NA
  LIPID^[@bib6]^              1998   0.80 ± 0.01 / 0.79 ± 0.01[\*](#tf25){ref-type="table-fn"}    NA
  Beishiuizen, ED^[@bib14]^   2004   0.78 ± 0.13 / 0.76 ± 0.12^[†](#tf26){ref-type="table-fn"}^   NA
  METEOR^[@bib13]^            2007   0.76 ± 0.12                                                  1.15 ± 0.19
  JART^[@bib15]^              2012   0.92 ± 0.22 / 0.87 ± 0.19^[‡](#tf27){ref-type="table-fn"}^   1.66 ± 0.59 / 1.61 ± 0.52^[‡](#tf27){ref-type="table-fn"}^
  Kim, KH^[@bib16]^           2013   0.61 ± 0.06 / 0.60 ± 0.06^[§](#tf28){ref-type="table-fn"}^   NA
  Ishigaki, Y^[@bib17]^       2014   0.86 ± 0.25 / 0.91 ± 0.30^[‖](#tf29){ref-type="table-fn"}^   1.26 ± 0.76 / 1.30 ± 0.58^[‖](#tf29){ref-type="table-fn"}^
  J-STARS                     2016   0.89 ± 0.15                                                  1.19 ± 0.32

IMT: intima media thickness; NA: not available

Pravastatin group / Placebo group

Cerivastatin group / Placebo group

Rosuvastatin / Pravastatin group

Atorvastatin10mg group / Atorvastatin 40 mg group

Pitavastatin group / Pravastatin group

###### Patient characteristics of previous studies

                                                       ACAPS                          CAIUS                    LIPID                     Beishiuizen                       METEOR                           JART                              KIM, K.H                          Ishigaki, Y                       J-STARS
  ---------------------------------------------------- ------------------------------ ------------------------ ------------------------- --------------------------------- -------------------------------- --------------------------------- --------------------------------- --------------------------------- --------------------------
  Year                                                 1994                           1996                     1998                      2004                              2007                             2012                              2013                              2014                              2016
  Country[\*](#tf30){ref-type="table-fn"}              USA                            Italy                    Australia, NZ             Netherland                        USA, Europe                      Japan                             Korea                             Japan                             Japan
  Study design                                         Lovastatin vs Placebo          Pravastatin vs Placebo   Pravastatin vs Placebo    Cerivastatin vs Placebo           Rosuvastatin vs Placebo          Rosuvastatin vs Pravastatin       Atorvastatin 10 mg vs 40 mg       Pitavastatin vs Pravastatin       Pravastatin vs No statin
  *N*                                                  919                            305                      522                       250                               982                              314                               70                                97                                793
  Age (years)                                          61.7 ± 8.3                     55.0 ± 6.0               61.0                      \*\*58.2 ± 11.4 / 58.8 ± 11.3     \*\*57.0 ± 6.2 / 57.0 ± 6.0      \*\*63.9 ± 8.9 / 63.3 ± 9.1       \*\*54.2 ± 12.5 / 52.6 ± 9.8      \*\*59.0 ± 8.8 / 60.0 ± 9.6       66.4 ± 8.3
  Male (%)                                             51.5                           53.0                     88.0                      47.2                              \*\*60.0/59.0                    \*\*49.7/49.0                     \*\*45.7/48.6                     \*\*41.2/52.2                     68.9
  BMI(kg/m^2^)^[†](#tf31){ref-type="table-fn"}^        26.3 ± 9.6 / 25.4 ± 4.6        24.7 ± 2.6               \-                        31.0 ± 6.0 / 31.0 ± 6.3           \*\*27.1 ± 4.0 / 27.5 ± 4.0      \-                                \*\*24.3 ± 2.9 / 24.9 ± 3.9       \*\*25.4 ± 4.5 / 26.0 ± 3.7       23.8 ± 3.0
  Systolic BP(mmHg)[\*](#tf30){ref-type="table-fn"}    130.6 ± 17.1                   133.6 ± 12.4             \-                        \-                                \*\*124.0 ± 13.4/ 125.0 ± 13.6   \*\*132.4 ± 17.0 / 130.0 ± 18.0   \-                                \*\*136.3 ± 18.0 / 134.1 ± 17.2   136.2 ± 17.3
  Diastolic BP(mmHg)[‡](#tf32){ref-type="table-fn"}    76.6 ± 8.9                     81.3 ± 7.5               \-                        \-                                \*\*77.0 ± 8.2 / 78.0 ± 8.5      \*\*76.7 ± 11.1 / 74.9 ± 13.5     \-                                \*\*75.9 ± 11.6/ 77.6 ± 10.1      78.8 ± 11.1
  Hypertension (%)                                     28.8                           \-                       \-                        50.4                              \-                               \*\*64.2/66.5                     \*\*17.1 / 14.3                   \*\*40.0 / 40.0                   77.6
  Diabetes mellitus (%)                                2.3                            \-                       5.0                       \-                                \-                               \*\*44.0/43.9                     \*\*5.7 / 8.6                     \-                                24.7
  CAD (%)^[§](#tf33){ref-type="table-fn"}^             \-                             \-                       75.0                      \-                                \-                               \*\*16.4/14.8                     100                               \*\*2.0 / 0                       4.4
  Smoking habit                                                                                                                                                                                                                                                                                                   
  Current (%)                                          11.9                           24.0                     \-                        24.4                              \-                               \*\*18.9/20.0                     \*\*37.1 / 28.6                   \*\*18.0 / 24.0                   17.5
  Former (%)                                           44.6                           \-                       \-                        \-                                \-                               \-                                \-                                \-                                35.3
  Never (%)                                            43.6                           \-                       \-                        \-                                \-                               \-                                \-                                \-                                46.7
  T-chol(mg/dl)^[‖](#tf34){ref-type="table-fn"}^       235.3 ± 23.2                   261.4 ± 23.6             \*\*207.3 / 220.8         \*\*216.6 ± 29.8 / 212.3 ± 27.8   \*\*229 ± 28.7 / 230 ± 27.7      \-                                \*\*188.8 ± 39.9 / 191.9 ± 34.0   \*\*244.8 ± 29.7 / 242.2 ± 34.3   210.5 ± 25.5
  HDL-chol, (mg/dl)^[‖](#tf34){ref-type="table-fn"}^   \*\*45.8 ± 11.6/ 58.3 ± 34.8   52.6 ± 11.6              \*\*36.7 / 36.3           \*\*46.8 ± 14.3/ 47.6 ± 15.1      \*\*50 ± 9.0 / 49 ± 9.2          \*\*54.2 ± 12.1 / 54.8 ± 13.2     \*\*52.9 ± 13.2 / 51.4 ± 8.5      \*\*54.2 ± 12.8 / 51.9 ± 9.6      53.0 ± 15.5
  LDL-chol,(mg/dl)^[‖](#tf34){ref-type="table-fn"}^    155.6 ± 15.5                   181.4 ± 19.7             \*\*149.7 / 155.5         \*\*137.2 ± 27.5 / 133.0 ± 27.5   \*\*155 ± 24.1 / 154 ± 24.2      \*\*163.8 ± 30.9 / 165.1 ± 29.1   \*\*127.5 ± 36.9 / 127.9 ± 31.1   \*\*163.4 ± 27.9 / 159.7 ± 25.6   130.6 ± 24.9
  TG,(mg/dl)^[‖](#tf34){ref-type="table-fn"}^          318.8 ± 150.6                  137.3 ± 49.6             \*\*157.7 / 146.1         \*\*166.5 ± 70.0 / 161.2 ± 70.0   \*\*126 ± 64.3 / 134 ± 67.8      \*\*149.6 ± 80.3 / 136.1 ± 69.8   \*\*129.7 ± 42.8 / 144.6 ± 54.2   \*\*147.4 ± 80.8 / 153.4 ± 88.1   141.3 ± 70.9
                                                       \*\*Men/Women                                           \*\*Pravastatin/Placebo   \*\*Cerivastatin/Placebo          \*\*Rosuvastatin/Placebo         \*\*Rosuvastatin/Pravastatin      \*\*Atorvastatin10 mg/ 40 mg      \*\*Pitavastatin/Pravastatin      

Mean ( ± Standard Deviation) or %

USA: United States of America; NZ: New Zealand.

BMI: Body mass index.

BP: blood pressure.

CAD: Coronary artery disease.

T-chol: Total cholesterol, HDL-chol: High density lipoprotein cholesterol, LDL-chol: Low density lipoprotein cholesterol, TG: triglyceride.

Age, smoking habit, category of blood pressure, DM, and HDL cholesterol were independently associated with mean IMT. These factors have been previously reported as atherosclerotic risk factors and have been strongly related to carotid IMT and atherothrombotic ischemic stroke^[@bib28]--[@bib34])^. However, the factors related to maximum IMT were somewhat different from those related to mean IMT in the present study; category of blood pressure was not significantly related to maximum IMT. This result may be due to different phenotypes of the atherosclerotic process between mean and maximum IMTs^[@bib35])^. Mean IMT reflects the hypertensive hypertrophic response of the medial cells, which seems to be related to changes in local shear stress, and represents a part of arterial remodeling that occurs at the early stage of atherosclerosis^[@bib36]--[@bib39])^, whereas maximum IMT often reflects plaques that mainly occur in the intima (endothelial cell, basal lamina, and subendothelial matrix), which represent the late stage of arteriosclerotic change related to inflammation, oxidation, endothelial dysfunction, and smooth muscle cell proliferation^[@bib40])^. Given this pathophysiological difference, hypertension may not have a significant influence on maximum IMT.

LDL cholesterol, a well-known atherosclerotic risk factor^[@bib41],\ [@bib42])^, was not significantly associated with mean and maximum IMTs in the present study, probably because enrolled patients had a limited range of total cholesterol (4.65--6.21 mmol/L) and relatively low LDL cholesterol levels compared with those in other trials (**[Supplementary Table 3](#T8){ref-type="table"}**). Recently, the ratio of LDL cholesterol/HDL cholesterol was indicated as a risk factor for atherosclerosis^[@bib43])^. Further multivariable analyses with this ratio, instead of LDL cholesterol and HDL cholesterol, showed that this ratio was independently associated with both mean and maximum IMTs in this cohort (**[Supplementary Tables 4](#T9){ref-type="table"}** and **[5](#T10){ref-type="table"}**).

###### Multiple regression analysis for mean intima-media complex thickness including LDL-cholesterol/ HDL-cholesterol and excluding LDL-cholesterol and HDL-cholesterol

  Variable                                                         Parameter Estimate   Standard Error   Pr \> \|t
  ---------------------------------------------------------------- -------------------- ---------------- -----------
  Age (/10 years)                                                  0.044                0.007            \<0.001
  LDL-cholestrol/HDL-cholesterol[\*](#tf35){ref-type="table-fn"}   0.022                0.006            0.001
  Smoking habit^[†](#tf36){ref-type="table-fn"}^                   0.022                0.007            0.003
  Category of blood pressure^[‡](#tf37){ref-type="table-fn"}^      0.022                0.008            0.006
  Diabetes mellitus                                                0.035                0.013            0.006

LDL-cholesterol: Low density lipoprotein cholesterol, HDL-cholesterol: High density lipoprotein cholesterol

Smoking habit including current smoker and past smoker

Category of blood pressure: Category 1, SBP ≥ 160 mmHg or DBP ≥ 100 mmHg; Category 2, SBP 140--159 mmHg or DBP 90--99 mmHg; Category 3, SBP \< 140 mmHg and DBP \< 90 mmHg

###### Multiple regression analysis for maximum intima-media complex thickness including LDL-cholesterol/ HDL-cholesterol and excluding LDL-cholesterol and HDL-cholesterol

  Variable                                                          Parameter Estimate   Standard Error   Pr \> \|t\|
  ----------------------------------------------------------------- -------------------- ---------------- -------------
  Age (/10 years)                                                   0.077                0.014            \< 0.001
  Smoking habit[\*](#tf38){ref-type="table-fn"}                     0.053                0.016            0.001
  Diabetes mellitus                                                 0.087                0.027            0.001
  LDL-cholestrol/HDL-cholesterol^[†](#tf39){ref-type="table-fn"}^   0.035                0.014            0.011
  Category of blood pressure^[‡](#tf40){ref-type="table-fn"}^       0.026                0.017            0.137

Smoking habit including current smoker and past smoker

LDL-cholesterol: Low density lipoprotein cholesterol, HDL-cholesterol: High density lipoprotein cholesterol

Category 1: SBP ≥ 160 mmHg or DBP ≥ 100 mmHg; Category 2: SBP 140--159 mmHg or DBP 90--99 mmHg; Category 3: SBP \< 140 mmHg and DBP \< 90 mmHg

One of the limitations of this trial is that all enrolled patients for the main J-STARS trial were not randomized to the J-STARS Echo Study, because only patients from institutes that had certified sonographers were enrolled. However, baseline characteristics of enrolled patients in the J-STARS Echo Study were almost similar to those of non-enrolled patients (**[Supplementary Table 1](#T6){ref-type="table"}**). The relatively low statin dosage in this trial, compared with the dosage used worldwide may also be a limitation. High-dose statin use is known to strongly suppress inflammation-related atherosclerotic factors, but there is still controversy regarding its efficacy and safety because of the small number of randomized, controlled trials involving statins^[@bib44])^.

Because there are scarce data regarding the relationship between IMT and statin use in patients with prior ischemic stroke, we examined this relationship in a large sample of Japanese noncardioembolic stroke patients. From this baseline data analyses, we showed factors associated with baseline IMTs and the similarity of baseline characteristics and IMTs between the pravastatin and control groups. We will examine the effect of the associated factors, such as age, smoking, category of blood pressure, HDL cholesterol, and DM, on the change in IMTs over 5 years of follow-up. Further observation of the relationship between statin use and sequential changes in IMT over 5 years will be conducted.

Conclusion
==========

In the Japanese stroke patients recruited for the J-STARS Echo Study, the overall mean and maximum IMTs were 0.89 ± 0.15 mm and 1.19 ± 0.32 mm, respectively. Age, smoking, hypertension, HDL cholesterol, and DM were associated with mean IMT, and those, except for hypertension, were associated with maximum IMT.
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